Another Atlas Venture-seeded biotech is out the door, $24 million series A in hand. Raze Therapeutics has mapped out the bold mission of pioneering a class of cancer therapeutics designed to halt tumor growth and survival by targeting mitochondrial one-carbon (1C) metabolism.